BioVersys AG (IPO)
Funding Details
Awarder
Inbox
Date Award
January 29, 2025
Vertical
Biopharmaceuticals
Funding URL
View Funding Page
Valuation
$212,900,000
Funding Amount
$75,000,000
Company Info
Traction
The IPO is expected to raise CHF 75 million, with a potential increase to CHF 80 million through an over-allotment option. The company has received commitments from GSK and the AMR Action Fund.
Organizations Involved
GSK, AMR Action Fund
Founders
Marc Gitzinger, Dr. Sergio Lociuro
Market
Antibacterial treatments for life-threatening infections
Location
Switzerland
Coinvestors
Glaxo Group Limited, AMR Action Fund
Company Description

BioVersys AG is a clinical-stage biopharmaceutical company dedicated to developing novel antibacterial treatments for life-threatening infections caused by multidrug-resistant (MDR) bacteria.

Links
Website
Back to HomeBack to Biopharmaceuticals DealsView Funding Announcement